A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062
Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.
The study assessed 420 Chinese patients, with 281 receiving xeligekimab and 139 on placebo. The study assessed PASI 75 and Physician Global Assessment (PGA) 0/1 at week 12, with sustained efficacy until week 52.
